Residual monotypic plasma cells in patients with waldenström macroglobulinemia after therapy

American Journal of Clinical Pathology

Volumn 135, Issue 3, 2011, Pages 365-373

  Barakat, Fareed H ^a   Medeiros, L Jeffrey ^a   Wei, Eric X ^b   Konoplev, Sergej ^a   Lin, Pei ^a   Jorgensen, Jeffrey L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Genoptix Inc   (United States)

Author keywords

Flow cytometry; Minimal residual disease; Plasma cells; Waldenstr m macroglobulinemia

Indexed keywords

BORTEZOMIB; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN M; MITOXANTRONE; PARAPROTEIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CELL POPULATION; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOCYTE; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PLASMA CELL; PLASMACYTOSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA; BONE MARROW CELL; CELL COUNT; CHROMOSOME BANDING PATTERN; IMMUNOLOGY; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; CELL COUNT; CHROMOSOME BANDING; FEMALE; HUMANS; IMMUNOGLOBULIN M; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; IMMUNOPHENOTYPING; LYMPHOCYTES; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PLASMA CELLS; TUMOR MARKERS, BIOLOGICAL; WALDENSTROM MACROGLOBULINEMIA;

EID: 79954431348     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP15YFULCZHZVH     Document Type: Article

References (17)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol. 2003;30:110-115. (Pubitemid 36506291)
2. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenström's macroglobulinemia. J Clin Oncol. 2005;23:1564-1577.
3. Kriangkum J, Taylor BJ, Treon SP, et al. Molecular characterization of Waldenström's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences. Clin Cancer Res. 2007;13:2005-2013. (Pubitemid 46649866)
4. Lin P, Hao S, Handy BC, et al. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol. 2005;123:200-205. (Pubitemid 40194080)
5. Vitolo U, Ferreri AJ, Montoto S. Lymphoplasmacytic lymphoma- Waldenström's macroglobulinemia. Crit Rev Oncol Hematol. 2008;67:172-185.
6. Varghese AM, Rawstron AC, Ashcroft AJ, et al. Assessment of bone marrow response in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:53-55.
7. Konoplev S, Medeiros LJ, Bueso-Ramos CE, et al. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am J Clin Pathol. 2005;124:414-420. (Pubitemid 41232928)
8. Mansoor A, Medeiros LJ, Weber DM, et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001;116:543-549. (Pubitemid 34450288)
9. Theriault C, Galoin S, Valmary S, et al. PCR analysis of immunoglobulin heavy chain (IgH) and TcR-gamma chain gene rearrangements in the diagnosis of lymphoproliferative disorders: results of a study of 525 cases. Mod Pathol. 2000;13:1269-1279. (Pubitemid 32014663)
10. Goteri G, Olivieri A, Ranaldi R, et al. Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome. Int J Immunopathol Pharmacol. 2006;19:421-431. (Pubitemid 44181964)
11. Robak T, Urbanska-Rys H, Jerzmanowski P, et al. Lymphoplasmacytic lymphoma with monoclonal gammopathy-related pseudo-Gaucher cell infiltration in bone marrow and spleen-diagnostic and therapeutic dilemmas. Leuk Lymphoma. 2002;43:2343-2350. (Pubitemid 35390334)
12. Smock KJ, Perkins SL, Bahler DW. Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment. Arch Pathol Lab Med. 2007;131:951-955. (Pubitemid 46906389)
13. Paiva B, Almeida J, Perez-Andres M, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom. 2010;78:239-252.
14. Morice WG, Chen D, Kurtin PJ, et al. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia. Mod Pathol. 2009;22:807-816.
15. Seegmiller AC, Xu Y, McKenna RW, et al. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol. 2007;127:176-181. (Pubitemid 46797173)
16. Lin P, Medeiros LJ. Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: an evolving concept. Adv Anat Pathol. 2005;12:246-255. (Pubitemid 41463805)
17. Chang H, Qi C, Trieu Y, et al. Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study. Clin Lymphoma Myeloma. 2009;9:36-38.